Mir Ali, MD
Pulmonary Disease · Clayton, NCNPI 1083800965
Payments from drug & device makers
Across 436 payments — averaging $337.72 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- GSK$71K
- Mylan Specialty L.p.$48K
- AstraZeneca$18K
- Sunovion Pharmaceuticals Inc.$7K
- Viiv Healthcare Company$2K
- Boehringer Ingelheim$258
- plus $2K from 24 others
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| GSK | 110 | $70,554 |
| Mylan Specialty L.p. | 120 | $48,279 |
| AstraZeneca | 64 | $17,777 |
| Sunovion Pharmaceuticals Inc. | 26 | $7,038 |
| Viiv Healthcare Company | 1 | $1,600 |
| Boehringer Ingelheim | 13 | $258 |
| Actelion Pharmaceuticals US, Inc. | 13 | $247 |
| United Therapeutics Corporation | 30 | $226 |
| Jazz Pharmaceuticals Inc. | 8 | $207 |
| Harmony Biosciences LLC | 4 | $142 |
| Genentech USA, Inc. | 8 | $136 |
| Regeneron Healthcare Solutions, Inc. | 4 | $82 |
| Verona Pharma, Inc. | 3 | $69 |
| Advanced Respiratory, Inc | 2 | $68 |
| Baxter Healthcare | 3 | $67 |
| Paratek Pharmaceuticals, Inc. | 3 | $59 |
| Insmed, Inc. | 2 | $56 |
| Philips North America LLC | 3 | $53 |
| Electromed, Inc. | 4 | $48 |
| Grifols USA, LLC | 2 | $38 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $37 |
| Novo Nordisk | 2 | $34 |
| Mallinckrodt Hospital Products Inc. | 2 | $30 |
| ANI Pharmaceuticals, Inc. | 1 | $28 |
| Mallinckrodt Enterprises LLC | 1 | $23 |
| Avadel CNS Pharmaceuticals, LLC | 1 | $22 |
| Viatris Specialty LLC | 1 | $22 |
| Merck | 1 | $21 |
| Novartis | 1 | $14 |
| Gilead | 1 | $12 |
How this compares
$147,248 in reported general payments places this provider in the 85th percentile of 393 pulmonary disease providers in North Carolina.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Other pulmonary disease in Clayton
- Selwyn SpangenthalCharlotte$7M
- Thomas SternHuntersville$5.2M
- Laurie SnyderDurham$3.8M
- Scott PalmerDurham$3.8M
- Michael PritchettPinehurst$2.2M
- Anup BanerjeeGastonia$2.1M
- Hubert FordChapel Hill$2M
- Murali RamaswamyGreensboro$2M
- Mikell JarrattGastonia$1.7M
- Lake MorrisonDurham$1.6M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.